Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vita Life SciencesASX:VLS +0.41%82 Earnings Yield (Joel Greenblatt) % is 13.44% as of Dec. 2025, which is 5% below its 10-year median of 14.10. GuruFocus rates ASX:VLS with a GF Score™ of 82/100 and a GF Value™ of A$2.49 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,015 Drug Manufacturers companies, Vita Life Sciences ranks better than 90.44% on this metric.
Vita Life Sciences's Enterprise Value for the quarter that ended in Dec. 2025 was A$109.92 Mil.
Vita Life Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$14.78 Mil. Vita Life Sciences's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 13.44%.
The historical rank and industry rank for Vita Life Sciences's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
ASX:VLS'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 7.77 Med: 14.1 Max: 24.01
Current: 14.72
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Vita Life Sciences was 24.01%. The lowest was 7.77%. And the median was 14.10%.
ASX:VLS's Earnings Yield (Joel Greenblatt) % is ranked better than 90.44% of 1015
companies
in the Drug Manufacturers industry
Industry Median: 3.22
vs ASX:VLS: 14.72
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Vita Life Sciences's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 14.47%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Vita Life Sciences (ASX:VLS) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Vita Life Sciences Earnings Yield (Joel Greenblatt) % Related Terms
Vita Life Sciences Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences Earnings Yield (Joel Greenblatt) % Chart
ASX:VLS vs ZTS, UTHR: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Earnings Yield (Joel Greenblatt) % falls into.
Vita Life Sciences Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Vita Life Sciencess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 13.44% mean?
Vita Life Sciences (ASX:VLS) has a Earnings Yield (Joel Greenblatt) % of 13.44% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Vita Life Sciences and its competitors. This is near median its historical median of 14.10. Over the past decade, Vita Life Sciences' Earnings Yield (Joel Greenblatt) % has ranged from 7.77 to 24.01. According to the industry distribution chart, Vita Life Sciences ranks #97 out of 1015 companies in the Drug Manufacturers industry, placing it in the top 9.6%.
Is Vita Life Sciences' Earnings Yield (Joel Greenblatt) % too high?
Vita Life Sciences' current Earnings Yield (Joel Greenblatt) % of 13.44% is near median its 10-year median of 14.10. Over the past 10 years, this metric has ranged from a low of 7.77 to a high of 24.01. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.22. Vita Life Sciences' value of 13.44% is 317.4% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #97 out of 1015 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vita Life Sciences has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #97 out of 1015 companies for Earnings Yield (Joel Greenblatt) %. This places Vita Life Sciences in the top 10% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.22. Vita Life Sciences' value of 13.44% is 317.4% above this benchmark. Historically, Vita Life Sciences' own Earnings Yield (Joel Greenblatt) % has ranged from 7.77 to 24.01 over the past decade. While the company's 10-year median is 14.10 vs. the industry median of 3.22, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.22, based on 1,015 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current Earnings Yield (Joel Greenblatt) % of 13.44% is 317.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Earnings Yield (Joel Greenblatt) % is 13.44%, which is near median its own 10-year median of 14.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.49, compared to a current price of A$2.46 — trading 1.2% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 13.44%, which is near median its 10-year median of 14.10 and 317.4% above the Drug Manufacturers industry median of 3.22. Vita Life Sciences' overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Earnings Yield (Joel Greenblatt) % is 13.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued.
The current stock price of A$2.46 is trading 1.2% below its estimated GF Value™ of A$2.49.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Earnings Yield (Joel Greenblatt) %: 13.44% (near median its 10-year median of 14.10)
GF Value™: A$2.49 vs. price of A$2.46 (1.2% below fair value)
Industry Position: 317.4% above the Drug Manufacturers median (#97 of 1015)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
82GF Score
Get the complete analysis for ASX:VLS
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
